New cancer pill enters human testing
NCT ID NCT05287399
Summary
This early-stage trial tested a new oral medication called ASC61 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose, see how the body processes the drug, and look for early signs that it might help control cancer. Researchers tested increasing doses to determine how much medicine patients could tolerate while monitoring for side effects and tumor response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research & Excellence (cCARE)
Fresno, California, 93720, United States
-
California Cancer Associates for Research & Excellence (cCARE)
San Marcos, California, 92069, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.